Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00741390 · ClinicalTrials.gov registry record · NA

Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose

A NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Becton, Dickinson and Company.

Completed
Registry status
NA
Development phase
250
Enrollment target
4
Study locations

NCT00741390: Completed NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Becton, Dickinson and Company.

NCT00741390 is a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1 that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 250 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00741390, a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, has completed, sponsored by Becton, Dickinson and Company.

COMPLETED
Registry status
NA
Development phase
250 participants
Enrollment target
4
Study locations

Study Summary

The procurement of blood for SMBG, usually via a finger stick, is considered by many patients to be the most painful portion of diabetes therapy. This has led to the marketing of smaller gauge lancets, lancing devices with variable depth settings and blood glucose sensors that require less blood for measurement. In this study, two main outcomes were evaluated: The first, which was assessed at Visit 1, was whether specific combinations of lancets and lancing devices would yield sufficient blood volume to allow valid assessment of diabetic subjects' glucose levels. The other outcome, assessed at Visit 2, was the level of pain perceived by subjects during lancing with specific combinations of lancets and lancing devices. During Visit 2, pain assessment was done using a Visual Analog Scale and such that for each lancet/lancing device, the lowest lancing device setting that yielded a valid BG reading for each subject during Visit 1 was used. A third outcome measure, overall comfort with lancing, was also assessed at Visit 2. A total of 5 combinations of lancets and lancing devices were evaluated. These were as follows: * BD/33G = BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips) * OTM/33G =OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips) * OTM/28G =OneTouch® Mini Lancet device / OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips) * OTU/28G = OneTouch® UltraSoft® Lancet device/OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips) * ACC/28G= Accu-Chek® Softclix Lancet device/Accu-Chek® Softclix 28G Lancet (BGM measured with Accu-Chek® Advantage BGM and Accu-Chek® Comfort Curve test strip) After enrollment and qualification, subjects were assigned to one of 4 intervention arms. The arm assignment deter

Primary Outcome

Number of subjects in whom valid meter reading was obtained with each device configuration. The primary outcome of a successful lancing is defined as whether or not a technician is able to use the lancing system to yield a blood sample of sufficient volume to yield a valid meter reading.

Interventions

  • DEVICE BD/33G
  • DEVICE OTM / 33G
  • DEVICE OTU/28G
  • DEVICE ACC/28G
  • DEVICE OTM/28G

Study Locations (4)

New Jersey

  • TKL Research, Inc. - Carlstadt
  • TKL Research, Inc - Paramus
  • TKL Research, Inc. - Ramsey

Colorado

  • Thomas J. Stephens & Associates - Colorado Springs

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2008-08
Est. Completion 2008-09
Phase NA
Becton, Dickinson and Company

33 total trials

What the finished NCT00741390 record still lists

NCT00741390 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 5 interventions - of which BD/33G is the first listed.

NCT00741390 reports a single indexed study location in New Jersey, Colorado.

Frequently Asked Questions

What is clinical trial NCT00741390 about?

NCT00741390 is a clinical study titled "Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose". The procurement of blood for SMBG, usually via a finger stick, is considered by many patients to be the most painful portion of diabetes therapy. This has led to the marketing of smaller gauge lancets, lancing devices with variable depth settings and blood glucose sensors that require less blood for...

What is the current status of trial NCT00741390?

This trial is currently completed. It is a NA study. The enrollment target is 250 participants. The study started on 2008-08. Estimated completion is 2008-09.

What conditions does trial NCT00741390 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1.

What interventions are being tested in trial NCT00741390?

The interventions under investigation include: BD/33G (DEVICE), OTM / 33G (DEVICE), OTU/28G (DEVICE), ACC/28G (DEVICE), OTM/28G (DEVICE).

Who is sponsoring clinical trial NCT00741390?

This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00741390 being conducted?

This trial has 4 study locations across Colorado, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00741390's enrollment target sits among peer trials

250 136th of 348 higher than 213 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00741390, the US trial registry maintained by the National Library of Medicine. NCT00741390 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.